Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9UGQ3
UPID:
GTR6_HUMAN
Alternative names:
Glucose transporter type 6
Alternative UPACC:
Q9UGQ3; A6NNU6; Q5SXD7; Q8NCC2
Background:
Solute carrier family 2, facilitated glucose transporter member 6, also known as Glucose transporter type 6, plays a crucial role in macrophage metabolism. It acts as a probable sugar transporter, regulating glycolysis in macrophages without transporting glucose itself. This unique function distinguishes it from other glucose transporters.
Therapeutic significance:
Understanding the role of Solute carrier family 2, facilitated glucose transporter member 6 could open doors to potential therapeutic strategies. Its involvement in macrophage metabolism regulation highlights its potential as a target for modulating immune responses and metabolic disorders.